Novo Nordisk is trading 10.5% down at DKK 296.25 after investors reacted negatively to a softer-than-expected 2026 outlook and slower projected growth in obesity-care revenues.
- Market concerns are mounting that future obesity drug sales and margins may not match prior bullish expectations, leading to a sharp reset in valuation.
- Despite strong recent performance, the updated guidance has prompted significant profit-taking amid ongoing volatility across the healthcare sector.